Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology using a proprietary discovery engine platform.
Ryvu Therapeutics SA
TAP Partner
Krakow,
Poland
Project Title
A phase 1b study of RVU120, a novel CDK8 inhibitor, in patients with AML or high-risk MDS
Program
Therapy Acceleration Program